Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
KANGNONG SEED
837403
CN Stock MarketDetailed Quotes
688488 Jiangsu Aidea Pharmaceutical
- 9.63
- -1.59-14.17%
Trading Apr 7 13:34 CST
4.05BMarket Cap-38.83P/E (TTM)
10.70High9.61Low134.14KlotVolume10.31Open11.22Pre Close135.12MTurnover3.19%Turnover RatioLossP/E (Static)420.78MShares17.3352wk High3.79P/B4.05BFloat Cap6.5852wk Low13.46Limit Up420.78MShs Float45.21Historical High8.98Limit Down9.72%Amplitude6.58Historical Low--Dividend TTM10.07Avg Price75.44KlotAsk--Div YieldTTM100Lot Size52.05KlotBid
Jiangsu Aidea Pharmaceutical News
Eddy Pharmaceutical\'s progress announcement on major asset restructuring matters
Jiangsu Eddy Pharmaceutical Co., Ltd. Major Asset Purchase Implementation Report
Eddy Pharmaceutical\'s announcement on the completion of the asset transfer of the object of the major asset purchase
Eddy Pharmaceutical\'s progress announcement on major asset restructuring matters
Announcement of Response to the Inquiry Letter on the Major Asset Purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. from Shanghai Stock Exchange
Draft (revised) report on major asset purchases by Jiangsu Aidea Pharmaceutical Co., Ltd.
Summary of Draft Revised Report on Significant Asset Acquisition of Jiangsu Aidea Pharmaceuticals Co., Ltd.
Independent Financial Advisor's Report on the Significant Asset Purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. by Minsheng Securities Co., Ltd.
Announcement on the Revision Explanation of the Draft Report on the Purchase of Significant Assets by Jiangsu Aidea Pharmaceutical
Summary of Draft Revised Report on Significant Asset Acquisition of Jiangsu Aidea Pharmaceuticals Co., Ltd.
Draft (revised) report on major asset purchases by Jiangsu Aidea Pharmaceutical Co., Ltd.
Independent Financial Advisor's Report on the Significant Asset Purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. by Minsheng Securities Co., Ltd.
Announcement of Response to the Inquiry Letter on the Major Asset Purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. from Shanghai Stock Exchange
Announcement on the Revision Explanation of the Draft Report on the Purchase of Significant Assets by Jiangsu Aidea Pharmaceutical
Jiangsu Aidea Pharmaceutical Announcement on the Progress of Major Asset Restructuring
The board of directors of Jiangsu Aidea Pharmaceutical has provided an explanation regarding the company's major assets restructuring, which is in compliance with the regulatory requirements of Article 4 of the Guidelines for the Supervision of Listed Companies No. 9 - the Regulations on Planning and Implementation of Major Asset Restructurings by Listed Companies.
The board of directors of Jiangsu Aidea Pharmaceutical has provided an explanation regarding this major asset restructuring that complies with Article 11 of the Management Measures for Major Asset Restructuring of Listed Companies.
Explanation from the board of directors of Jiangsu Aidea Pharmaceutical regarding the company's major asset restructuring, which does not constitute a re-listing as defined in Article 13 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.
Independent Financial Advisor's Report on the Significant Asset Purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. by Minsheng Securities Co., Ltd.
Major asset purchase report (draft) of Jiangsu Aidea Pharmaceutical Co., Ltd.